Experimental combo targets Hard-to-Treat tumors
NCT ID NCT06182579
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-stage study tested a new drug called RiMO-401 given as an injection directly into tumors, combined with radiation, for people with advanced solid cancers that could not be cured. Only 5 participants were enrolled before the study was stopped. The main goal was to find a safe dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.